Stockscreener 앱 받기
1.30
0.00%
0.00
Dermata Therapeutics Inc 주식(DRMA)의 최신 뉴스
DRMAW Dermata quarterly earnings core metrics remain unavailable as investors await full official operational and financial disclosures.Social Momentum Signals - Newser
Dermata Therapeutics, Inc.Common Stock (NQ: DRMA - FinancialContent
RBC Capital initiates Dermata Therapeutics stock at outperform By Investing.com - Investing.com South Africa
RBC Capital initiates Dermata Therapeutics stock at outperform - Investing.com
Dermata (DRMA) Stock Valuation | Dermata Therapeutics posts narrower loss, 3.2 pct EPS beatSurprise Factor - Cổng thông tin điện tử tỉnh Lào Cai
Bigger Capital now holds 75,200 shares after sales (NASDAQ: DRMA) - Stock Titan
Dermata (DRMA) Stock Hot Topic (Institutional Selling) 2026-04-20Analyst Consensus - Cổng thông tin điện tử tỉnh Lào Cai
Dermata Therapeutics (NASDAQ: DRMA) seeks approval for warrants and equity plan at 2026 meeting - Stock Titan
Patterns Watch: Does LogProstyle Inc have strong fundamentalsDip Buying & Expert Approved Momentum Ideas - baoquankhu1.vn
Sentiment Watch: Will Dermata Therapeutics Inc Equity Warrant outperform the market in YEARWeekly Trade Analysis & High Accuracy Swing Trade Signals - baoquankhu1.vn
Are investors bearish on Dermata (DRMA) Stock | Price at $1.25, Up 2.87%Attention Driven Stocks - Newser
WSBCO Should I Buy - Intellectia AI
Bond Watch: Is Dermata Therapeutics Inc Equity Warrant stock risky to hold nowRate Cut & Precise Swing Trade Alerts - baoquankhu1.vn
Moving Averages: Is Dermata Therapeutics Inc Equity Warrant gaining market share2026 Institutional & Verified Technical Signals - baoquankhu1.vn
Dermata Therapeutics Inc. (DRMA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Market Review: Will Dermata Therapeutics Inc benefit from AI trendsEntry Point & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Can Dermata (DRMA) Stock Go Higher | Price at $1.24, Up 2.07%Continuation Pattern - Newser
Aug Sectors: Is Dermata Therapeutics Inc Equity Warrant benefiting from innovation trendsTrade Exit Report & Weekly Top Gainers Trade List - baoquankhu1.vn
Targets Report: Is Dermata Therapeutics Inc Equity Warrant stock undervalued right nowWeekly Stock Report & Daily Volume Surge Signals - baoquankhu1.vn
What limits growth of Xeris (XERS) Stock | XERS Q4 Earnings: Beats Estimates by $0.02Community Risk Signals - Cổng thông tin điện tử tỉnh Lào Cai
Gap Down: Will Bukit Jalil Global Acquisition 1 Ltd Equity Warrant benefit from green energy policies2026 Trends & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Analyst Calls: Whats the outlook for Dermata Therapeutics Incs sector2026 Price Targets & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
[PRE 14A] Dermata Therapeutics, Inc. Preliminary Proxy Statement - Stock Titan
Take Profit: Is Dermata Therapeutics Inc Equity Warrant benefiting from innovation trendsQuarterly Risk Review & Reliable Intraday Trade Plans - baoquankhu1.vn
Market Moves: Can Dermata Therapeutics Inc Equity Warrant weather a recessionRate Hike & Smart Investment Allocation Insights - baoquankhu1.vn
Is Dermata (DRMA) Stock Losing Momentum | Price at $1.32, Up 2.33%Expert Stock Picks - Xã Thanh Hà
CAS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
ALYAF Should I Buy - Intellectia AI
DRMA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Plus Therapeutics Inc (XMP0.DU) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Dermata shares rise after USPTO issues patent notice of allowance - MSN
DRMA Should I Buy - Intellectia AI
Dermata receives Australian patent acceptance for topical filler - Investing.com Australia
01171 Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Dermata Therapeutics Receives Australian Patent Acceptance for Bioneedle Dermal Filler Delivery System - geneonline.com
Dermata receives Australian patent acceptance for topical filler By Investing.com - Investing.com Canada
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System - The Batesville Daily Guard
Dermata clears Australian patent hurdle for topical dermal fillers - Stock Titan
DRMAW Stock Analysis: Dermata Therapeutics Inc. Warrant down 5.88% to $0.02 near key support levels - Newser
Maxim Group Maintains Dermata Therapeutics(DRMA.US) With Buy Rating, Cuts Target Price to $4 - Moomoo
TCFP Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Guidance Update: Will Dermata Therapeutics Inc Equity Warrant benefit from AI trendsMarket Sentiment Report & Verified Short-Term Plans - baoquankhu1.vn
Tangible book value per share of Dermata Therapeutics, Inc. – NASDAQ:DRMAW - TradingView
Total debt per share of Dermata Therapeutics, Inc. – NASDAQ:DRMAW - TradingView
Aug Levels: Will Dermata Therapeutics Inc benefit from seasonality2026 Summary & Stepwise Trade Signal Guides - baoquankhu1.vn
Quarterly Trades: Is Dermata Therapeutics Inc stock forming a cup and handleQuarterly Portfolio Review & Weekly Watchlist of Top Performers - baoquankhu1.vn
Dermata Therapeutics Reports Increased Losses in FY Earnings - Intellectia AI
Dermata Therapeutics 2025 Financial Update - AlphaStreet
Dermata Therapeutics Inc stock rises amid market gains - Intellectia AI
Southland Holdings, Inc. (SLND) Reports Wider Q4 Loss Than Expected - news.alphastreet.com
Dermata Therapeutics Announces Strategic Pivot to DTC Skincare with Tome Brand and Plans 2026 Product Launch - Minichart
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025 - Bitget
Dermata Therapeutics 10-K: $7.56M net loss, operating expenses $7.77M - TradingView
0.78%
3.01%
자본화:
|
볼륨(24시간):